USD 8.8
(-3.27%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 12.02 Million USD | 73.66% |
2022 | 6.92 Million USD | -34.31% |
2021 | 10.54 Million USD | 143.03% |
2020 | 4.33 Million USD | -8.08% |
2019 | 4.71 Million USD | 322.76% |
2018 | 1.11 Million USD | -2.02% |
2017 | 1.13 Million USD | 14.36% |
2016 | 996 Thousand USD | 109.43% |
2015 | 475.58 Thousand USD | 95.55% |
2014 | 243.2 Thousand USD | -79.64% |
2013 | 1.19 Million USD | 207.72% |
2012 | -1.1 Million USD | 0.0% |
2011 | - USD | -100.0% |
2010 | 1.00 USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q3 | - USD | 0.0% |
2024 Q2 | - USD | -100.0% |
2024 Q1 | 7.67 Million USD | -36.19% |
2023 Q2 | 10.21 Million USD | 36.58% |
2023 FY | 12.02 Million USD | 73.66% |
2023 Q1 | 7.47 Million USD | 7.99% |
2023 Q4 | 12.02 Million USD | -23.19% |
2023 Q3 | 15.65 Million USD | 53.29% |
2022 Q1 | 12.42 Million USD | 17.86% |
2022 FY | 6.92 Million USD | -34.31% |
2022 Q4 | 6.92 Million USD | 69.91% |
2022 Q3 | 4.07 Million USD | 38.18% |
2022 Q2 | 2.94 Million USD | -76.26% |
2021 Q1 | 9.18 Million USD | 111.81% |
2021 Q3 | 10.34 Million USD | -4.75% |
2021 Q4 | 10.54 Million USD | 1.88% |
2021 FY | 10.54 Million USD | 143.03% |
2021 Q2 | 10.86 Million USD | 18.23% |
2020 Q2 | 4.08 Million USD | -28.86% |
2020 FY | 4.33 Million USD | -8.08% |
2020 Q1 | 5.73 Million USD | 21.62% |
2020 Q4 | 4.33 Million USD | 4.05% |
2020 Q3 | 4.16 Million USD | 2.11% |
2019 Q4 | 4.71 Million USD | 23.51% |
2019 Q3 | 3.82 Million USD | 8.8% |
2019 FY | 4.71 Million USD | 322.76% |
2019 Q1 | 3.59 Million USD | 222.31% |
2019 Q2 | 3.51 Million USD | -2.39% |
2018 Q4 | 1.11 Million USD | -33.17% |
2018 Q3 | 1.67 Million USD | -19.36% |
2018 Q2 | 2.07 Million USD | 4.18% |
2018 Q1 | 1.98 Million USD | 74.54% |
2018 FY | 1.11 Million USD | -2.02% |
2017 FY | 1.13 Million USD | 14.36% |
2017 Q3 | 689 Thousand USD | -22.5% |
2017 Q1 | 1.12 Million USD | 13.35% |
2017 Q4 | 1.13 Million USD | 65.31% |
2017 Q2 | 889 Thousand USD | -21.26% |
2016 Q3 | 78.53 Thousand USD | -80.55% |
2016 FY | 996 Thousand USD | 109.43% |
2016 Q2 | 403.77 Thousand USD | -12.46% |
2016 Q1 | 461.26 Thousand USD | -3.01% |
2016 Q4 | 996 Thousand USD | 1168.29% |
2015 Q2 | 464.34 Thousand USD | 178.44% |
2015 FY | 475.58 Thousand USD | 95.55% |
2015 Q4 | 475.58 Thousand USD | 2.84% |
2015 Q3 | 462.45 Thousand USD | -0.41% |
2015 Q1 | 166.76 Thousand USD | -31.43% |
2014 Q4 | 243.2 Thousand USD | -64.44% |
2014 Q2 | 582.55 Thousand USD | -55.32% |
2014 Q3 | 683.94 Thousand USD | 17.4% |
2014 Q1 | 1.3 Million USD | 9.16% |
2014 FY | 243.2 Thousand USD | -79.64% |
2013 Q1 | - USD | 100.0% |
2013 Q2 | 244.39 Thousand USD | 0.0% |
2013 Q4 | 1.19 Million USD | 107.3% |
2013 Q3 | 576.19 Thousand USD | 135.76% |
2013 FY | 1.19 Million USD | 207.72% |
2012 Q4 | -1.1 Million USD | 0.0% |
2012 FY | -1.1 Million USD | 0.0% |
2011 FY | - USD | -100.0% |
2010 FY | - USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Agios Pharmaceuticals, Inc. | 19.07 Million USD | 36.968% |
Amicus Therapeutics, Inc. | 59.69 Million USD | 79.858% |
Atara Biotherapeutics, Inc. | 9.7 Million USD | -23.882% |
bluebird bio, Inc. | 22.91 Million USD | 47.537% |
Cara Therapeutics, Inc. | 2.82 Million USD | -326.232% |
Imunon, Inc. | - USD | -Infinity% |
Editas Medicine, Inc. | - USD | -Infinity% |
IQVIA Holdings Inc. | - USD | -Infinity% |
Mettler-Toledo International Inc. | 385.86 Million USD | 96.884% |
Myriad Genetics, Inc. | 20.1 Million USD | 40.179% |
Neurocrine Biosciences, Inc. | 38.3 Million USD | 68.606% |
Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 84.467% |
Verastem, Inc. | - USD | -Infinity% |
Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.855% |
Waters Corporation | 516.23 Million USD | 97.671% |
Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.764% |
Biogen Inc. | 2.52 Billion USD | 99.524% |
Nektar Therapeutics | 16.1 Million USD | 25.321% |
Perrigo Company plc | 1.14 Billion USD | 98.946% |
Dynavax Technologies Corporation | 53.29 Million USD | 77.437% |
Illumina, Inc. | 587 Million USD | 97.952% |
Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
Iovance Biotherapeutics, Inc. | 10.37 Million USD | -15.927% |
Heron Therapeutics, Inc. | 42.11 Million USD | 71.446% |
Unity Biotechnology, Inc. | - USD | -Infinity% |
BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 98.914% |
Sangamo Therapeutics, Inc. | - USD | -Infinity% |
Evolus, Inc. | 10.99 Million USD | -9.329% |
Adicet Bio, Inc. | - USD | -Infinity% |
Aclaris Therapeutics, Inc. | - USD | -Infinity% |
Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.534% |
Esperion Therapeutics, Inc. | 65.62 Million USD | 81.677% |
FibroGen, Inc. | 41.56 Million USD | 71.072% |
Agilent Technologies, Inc. | 1.03 Billion USD | 98.834% |
OPKO Health, Inc. | 65.69 Million USD | 81.698% |
Homology Medicines, Inc. | - USD | -Infinity% |
Geron Corporation | - USD | -Infinity% |
Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 86.512% |
Exelixis, Inc. | 17.32 Million USD | 30.589% |
Viking Therapeutics, Inc. | - USD | -Infinity% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | - USD | -Infinity% |
Zoetis Inc. | 2.56 Billion USD | 99.531% |
Axsome Therapeutics, Inc. | 15.13 Million USD | 20.555% |
Abeona Therapeutics Inc. | -2.44 Million USD | 591.98% |
Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 98.372% |
Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 57.699% |
Sarepta Therapeutics, Inc. | 322.85 Million USD | 96.276% |
Corcept Therapeutics Incorporated | 7.73 Million USD | -55.55% |
Halozyme Therapeutics, Inc. | 127.6 Million USD | 90.577% |
Blueprint Medicines Corporation | 21.22 Million USD | 43.344% |
Insmed Incorporated | 83.24 Million USD | 85.556% |
TG Therapeutics, Inc. | 39.82 Million USD | 69.806% |
Incyte Corporation | 62.97 Million USD | 80.906% |
Emergent BioSolutions Inc. | 328.9 Million USD | 96.344% |